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We studied the biochemical mechanisms associated with inhibition and resistance to a 4,5-dihydroxypyrim-
idine carboxylate that inhibits the hepatitis C virus (HCV) RNA-dependent RNA polymerase NS5B. On the
basis of the structure of the pharmacophore, it has been suggested that these compounds may act as
pyrophosphate (PPi) mimics. We monitored nucleotide incorporation events during the elongation phase and
showed that the polymerase activity of wild-type NS5B was inhibited by the dihydroxypyrimidine at a 50%
inhibitory concentration (IC50) of 0.73 M. Enzymes with the G152E or P156L mutation, either of which
confers resistance to this compound, showed four- to fivefold increases in IC50s. The inhibitor was competitive
with respect to nucleotide incorporation. It was likewise effective at preventing the PPi-mediated excision of an
incorporated chain terminator in a competitive fashion. In the absence of the dihydroxypyrimidine, the
reaction was not significantly affected by the G152E or P156L mutation. These data suggest that the resistance
associated with these two mutations is unlikely due to an altered interaction with the pyrophosphate-mimicking
domain of the compound but, rather, is due to altered interactions with its specificity domain at a region
distant from the active site. Together, our findings provide strong experimental evidence that supports the
notion that the members of this class of compounds can act as PPi mimics that have the potential to
mechanistically complement established nucleoside and nonnucleoside analogue inhibitors.
Hepatitis C virus (HCV) is a major public health problem,
with an estimated 170 million people worldwide being infected
with the virus (9). Chronic infection with HCV can lead to the
development of severe liver disease, including cirrhosis and
hepatocellular carcinoma (HCC) (17). The current standard of
care for those who are in need of antiviral therapy consists of
a combination of pegylated alpha interferon and the nucleo-
side analogue ribavirin (21). However, the clinical use of both
components is associated with toxic side effects, and by far, not
everyone benefits from treatment (4, 11).
Nonstructural proteins NS2 through NS5B represent impor-
tant targets for current drug discovery and development efforts
aimed at improving anti-HCV therapy. Various classes of in-
hibitors of the HCV RNA-dependent RNA polymerase NS5B
have been developed. These compounds can be further
grouped into nonnucleoside analogue inhibitors (NNIs) and
nucleoside analogue inhibitors (NIs). The two classes of inhib-
itors target different stages of RNA synthesis. The HCV NS5B
protein is capable of initiating RNA synthesis de novo, i.e., in
the absence of a primer (12, 14, 23, 25, 33). At this early stage,
productive initiation complexes are fragile and RNA synthesis
is distributive. After four to six nucleotide incorporation
events, at which point the enzyme switches to the elongation
stage, conformational changes render the polymerization pro-
cess highly processive (18). NNIs were shown to interfere with
steps prior to or during the initiation of RNA synthesis (7, 10,
19, 30, 31). Although the binding sites and the detailed mech-
anisms of action can differ among the various families of these
compounds, they do not appear to affect RNA elongation. In
contrast, the triphosphate form of nucleoside analogue in-
hibitors binds to the active site and competes with the nat-
ural counterpart for incorporation into the growing RNA
chain, preferentially during elongation. Several NIs have
advanced into clinical trials, including prodrugs of 2-deoxy-
2-fluoro-2-C-methylcytidine (PSI-6130) and 2-C-methyl-
cytidine (NM283) (16). While the former is currently being
evaluated in phase II clinical trials, the development of the
latter has been placed on hold.
Derivatives of 4,5-dihydroxypyrimidine carboxylic acid and
,-diketoacid are commonly referred to as pyrophosphate
(PPi) mimics. These compounds may likewise act at the active
site of the HCV RNA-dependent RNA polymerase NS5B (15,
29). The structures suggest that the members of the two families
of compounds are able to coordinate the two divalent metal ions
in a fashion similar to that which one would predict for the PPi
product that is released from the complex following nucleotide
incorporation (5). However, it remains to be studied how these
compounds interfere with nucleotide binding and nucleotide in-
corporation and whether or how the reverse reaction, i.e., pyro-
phosphorolysis, might be affected. Our recent studies have shown
that the NS5B protein of HCV is capable of excising chain-
terminating nucleotides in the presence of physiologically rele-
vant concentrations of PPi (6). The excision reaction can compro-
mise the efficacy of nucleotide analogues, and PPi mimics may
have the potential to counteract these effects.
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To address these questions, we have studied the biochemical
mechanisms associated with both the inhibition of RNA syn-
thesis and resistance to a prototype pyrimidine, herein referred
to as compound A (Fig. 1A). The inhibitor contains two dis-
tinct domains: the anchor domain, which is implicated in in-
teractions with the two catalytic metal ions at the active site,
and the specificity domain, which provides additional contacts
at distant regions of the enzyme (28). Here we demonstrate
that compound A is able to inhibit both nucleotide incorpora-
tion and the PPi-mediated excision of nucleotide analogues.
Increasing concentrations of natural nucleotides and PPi, re-
spectively, counteract these inhibitory effects, which points to a
competitive mechanism of action. Moreover, the P156L and
G152E mutations in HCV NS5B (Fig. 1B), which were previ-
ously shown to decrease susceptibility to dihydroxypyrimidines
in cell-based assays, also compromise the inhibitory effects of
compound A in cell-free assays (32). Both the unique resis-
tance profile and the ability of the compound to mechanisti-
cally complement other classes of NS5B inhibitors warrant
further investigation in the development of PPi mimics as an-
tiviral agents.
MATERIALS AND METHODS
Nucleic acid, nucleotides, and inhibitors. The RNA sequence used in this
study as a template for NS5B-mediated RNA synthesis was as follows: 5AAC
AGUUUCCUUUUCUCUCC-3 (Trilink). The sequence contained a single site
for the incorporation of a cytidine analogue at position 16 (opposite G, un-
derlined). The RNA was purified on a 12% polyacrylamide–7 M urea gel con-
taining 50 mM Tris-borate (pH 8) and 1 mM EDTA. It was then eluted overnight
from gel slices in a buffer containing 500 mM ammonium acetate and 0.1% SDS.
A 5-GG-3 dinucleotide (Trilink) was used as a primer. Labeling of the 5 end
of the primer with [-32P]ATP was carried out with T4 polynucleotide kinase
(Invitrogen). Nucleoside triphosphates (NTPs) were treated with inorganic
pyrophosphatase to prevent PPi contamination. The nucleotide analogue 2-C-
methyl-CTP and the dihydroxypyrimidine carboxylate (compound A) were pro-
vided by Merck.
Expression and purification of HCV NS5B. The HCV NS5B sequence was
inserted into the expression vector pET-21 (Novagen), in which the C-terminal
21 amino acids were deleted and a His tag was added to the C terminus. The
plasmid encoding the C-terminal truncated enzyme (21) was transformed into
Escherichia coli BL21(DE3) cells. The induction of protein expression was un-
dertaken with the addition of 0.25 mM isopropyl--D-thiogalactopyranoside at
25°C. Protein was isolated by using an Ni-chelating Sepharose column. The
generation of mutant enzymes with the P156L and G152E mutations was ac-
complished through site-directed mutagenesis with a Stratagene Quick-Change
kit, according to the manufacturer’s directions. The presence of the mutations
was confirmed by sequencing at the Genome Quebec Innovation Center.
RNA synthesis. The reaction mixtures contained 1 M RNA template, 2 M
HCV NS5B, 0.2 M radiolabeled GG primer, and 10 M NTPs. For reactions
requiring chain termination at position 16, 10 M 2-C-methyl-CTP was in-
cluded. Reactions were carried out in a buffer containing 20 mM Tris (pH 7.5),
50 mM NaCl, 1 mM dithiothreitol, 0.2 mM MnCl2, and 6 mM MgCl2. The
incubation time for the synthesis experiments was 40 min. The reactions were
stopped by the addition of 100 mM EDTA in formamide. The samples were heat
denatured at 95°C for 5 min and resolved on 12% polyacrylamide–7 M urea gels.
The concentration of dihydroxypyrimidine carboxylate required to inhibit 50% of
full-length product formation (IC50) was calculated by using Prism software
(GraphPad, Inc). All assays were repeated a minimum of three times.
Pyrophosphorolysis and rescue of RNA synthesis. After completion of the
chain-termination reaction, pyrophosphorolytic excision of 2-C-methyl-CTP was
FIG. 2. Synthesis of RNA by wild-type (WT) HCV NS5B and mu-
tants with the G152E or P156L mutation. (A) Schematic of RNA
synthesis reaction. (B) RNA synthesis by wild-type NS5B and the
enzymes with the G152E or P156L mutation was monitored over a
period of 45 min.FIG. 1. (A) Structure of compound A. (B) Model of the HCV
NS5B active site with bound template (orange) and NTP. Active-site
residues D318 and D319 are shown in red, while the G152 and P156
residues are highlighted in blue.
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carried out with the addition of 1.25 mM PPi. This removes the chain terminator,
but in the absence of the competing natural nucleotide CTP and additional
nucleotide pools, no further RNA synthesis occurs, although the chain termina-
tor may be reincorporated at the same position. The rescue reaction included 300
M PPi to excise the chain terminator as well as 10 M UTP and 100 M the
competing natural nucleotide CTP to displace the chain terminator and rescue
RNA synthesis, resulting in a full-length product.
Competition with inhibitor. To determine whether compound A can act com-
petitively with either nucleotide substrates or PPi, the IC50 of the PPi analogue
was determined in the presence of different concentrations of nucleotides or PPi.
Of note, the enzyme does not dissociate from the stalled elongation complex;
thus, the rates are independent of the enzyme concentration, and consequently,
reactions cannot be carried out under conditions that allow multiple turnovers
(steady-state conditions) (6). To look at competition with nucleotides, synthesis
to position 16 of the template was promoted with the addition of 3 M each
GTP and ATP and 16 nM CTP. Further synthesis requires the addition of UTP,
which yields a full-length product at position 20. The IC50 of compound A
during the elongation reaction was determined in the presence of 0.1, 1, and 5
M UTP. Inhibitor concentrations ranged up to 1,120 nM. To study competition
with PPi, a similar assay was carried out. Briefly, different concentrations of PPi
(50 M, 100 M, 500 M) were used for a rescue reaction, and the IC50 of the
inhibitor was determined at each concentration. The inhibitor concentrations in
the rescue assay ranged from 0 to 2.25 M.
RESULTS
Inhibition of RNA synthesis. We monitored RNA synthesis
in the absence and presence of compound A with purified
HCV NS5B using a 20-mer heteropolymeric model template
and a dinucleotide primer (5-GG-3) (Fig. 2A). The template
was designed to allow incorporation of the nonobligate chain
terminator 2-C-methyl-CMP (2-C-Me-CMP) at a single po-
sition, which, in turn, facilitates the study of PPi-mediated
excision and its inhibition. Initially, we studied RNA synthesis
by wild-type NS5B and enzymes containing the G152E and
P156L mutations in the absence of any inhibitor. Extension of
the GG primer leads to a full-length product as well as a
product further extended by a single position. This extended
product may arise through the terminal transferase activity of
HCV NS5B, as has been reported previously (2, 24). The level
of full-length product formed over a 45-min period was similar
for all enzymes, indicating that the mutations do not affect
activity (Fig. 2B). We then examined the effects of increasing
concentrations of compound A on RNA synthesis in the con-
text of both wild-type HCV NS5B and the mutant enzymes to
test whether the resistant phenotype can be translated in bio-
chemical terms (Fig. 3A). With wild-type HCV NS5B, we mea-
sured IC50s of approximately 700 nM on the basis of decreases
in the formation of the full-length product compared to the
level of formation for the control in the absence of inhibitor.
The lack of additional pausing sites in the presence of inhib-
FIG. 3. Inhibition of RNA synthesis by compound A. (A) RNA synthesis of a chain-terminated product (position 16) by wild-type NS5B or
the mutant enzymes with the G152E or P156L mutation was examined in the presence of increasing concentrations of compound A up to 200 M.
(B) Graphic representation of the data shown in panel A. IC50s for inhibition of the wild-type and mutant enzymes are based on full-length RNA
synthesis. Data points show the means and standard deviations determined from three independent experiments.
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itor suggests that RNA synthesis is affected throughout the
process of RNA synthesis, during initiation and elongation.
The G152E mutation increased the IC50 approximately
fourfold, while the P156L mutation increased the values
fivefold (Fig. 3B).
To provide further insight into the mechanism of resistance,
we studied the potential effects of the two mutations on the
PPi-mediated excision of incorporated 2-C-Me-CMP. RNA
synthesis with limited nucleotide pools and the nucleotide an-
alogue caused chain termination at position 16. The reaction
was allowed to proceed to near completion, and the subse-
quent addition of PPi and a complete set of natural nucleotides
could then initiate excision and the rescue of RNA synthesis
(Fig. 4A). Increasing concentrations of PPi resulted in in-
creases in excision and the rescue of RNA synthesis with each
of the three enzymes (Fig. 4B). The amount of excision was
similar for wild-type NS5B and the two mutant enzymes (Fig.
4C). These findings suggest that neither G152E nor P156L
affects the binding of PPi. By extension, the two mutations do
not appear to interfere with the anchor domain of compound
A; rather, they may affect contacts with the specificity domain.
Inhibition of PPi-mediated excision of nucleotide analogues.
To study whether compound A is able to inhibit the combined
excision and rescue reaction, we added increasing concentra-
tions of the inhibitor to the reaction mixture containing PPi
and nucleotides. Wild-type HCV NS5B was inhibited during
excision and rescue, with the IC50s being approximately 1.7
M, which is similar to the inhibition values measured during
the RNA synthesis reaction (Fig. 5A). The two mutant en-
zymes again showed increases in IC50s of at least an order of
magnitude. To test whether the inhibitor can directly affect
pyrophosphorolytic cleavage, we assayed the PPi-mediated ex-
cision of the chain terminator in the absence of the nucleotide
substrates that are required for the rescue reaction. Of note,
excision in the absence of competing nucleotides is generally
inefficient compared with the efficiency of excision achieved in
the combined excision-rescue reaction. The facile reincorpo-
ration of the chain terminator diminishes the net formation of
the shorter reaction product. As a consequence, the two mu-
tant enzymes appear to be completely resistant to the inhibitor
under these conditions. However, compound A is able to in-
hibit the reaction with wild-type NS5B, which demonstrates
FIG. 4. PPi-dependent excision of a chain terminator and rescue of RNA synthesis. (A) The schematic depicts a chain-terminated product after
addition of only GTP, ATP, and 2-C-methyl-CTP. Following this reaction, the excision of the chain terminator and the rescue of RNA synthesis
are initiated with the addition of PPi, UTP, and CTP. (B) Excision and rescue occur in a dose-dependent manner with the addition of up to 320
M PPi. The reaction is shown for wild-type NS5B and the mutant enzymes. Lanes C, the excision reaction alone, which produces a product at
position 15. (C) The amount of excised and rescued product was quantified as the amount of product at position 20 as a percentage of the total
amount of product in the lane. Data points are the means  standard deviations for three independent experiments.
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that the inhibitor can interfere directly with pyrophosphoroly-
sis (Fig. 5B).
Mechanism of inhibition. The observation that compound A
inhibits both RNA synthesis and pyrophosphorolysis provides
support for the notion that the inhibitor can coordinate the
divalent metal ions at the active site in a fashion similar to that
for the PPi product or the phosphates of an incoming nucleo-
tide. Hence, the binding of compound A and the nucleotide
substrate is likely to be competitive in nature. To test this
hypothesis, we measured the effect of the pyrimidine at differ-
ent concentrations of the nucleotide substrate. RNA synthesis
was halted at position 16, by omitting the required UTP from
the reaction mixture. In contrast to previously described ex-
periments, chain-terminating nucleotides were not included in
the reaction mixture. The continuation of RNA synthesis in the
presence of three different concentrations of UTP and increas-
ing concentrations of compound A was then monitored (Fig.
6A). We measured increasing IC50s at higher concentrations of
the nucleotide substrate, which suggests a competitive mecha-
nism of inhibition of RNA synthesis (Table 1). We obtained
essentially the same result when we looked at the inhibition of
the combined excision-rescue reaction with different concen-
trations of PPi, which also confirms a competitive mechanism
of inhibition of the reverse reaction (Fig. 6B).
DISCUSSION
In the study described here, we elucidated the possible
mechanisms of action and resistance associated with the inhi-
bition of HCV NS5B by a prototype dihydroxypyrimidine car-
boxylate, referred to as compound A. Our findings provide
strong evidence that members of this class of compounds act as
PPi mimics. We show that compound A interferes directly with
the PPi-mediated excision of incorporated chain terminators.
The excision of an incorporated nucleotide analogue is inhib-
ited, with the IC50s being in the low-micromolar range. Higher
concentrations of PPi lead to higher IC50s, which is indicative
of a steric conflict. The geometry of the dihydroxypyrimidine
carboxylate anchor region may interact with the two divalent
metal ions at the active site in a fashion similar to that de-
scribed in crystallographic models for PPi (8, 27). Together, the
data point to overlapping binding sites; however, the proper-
ties of PPi and compound A are entirely different. PPi, as the
product of a nucleotidyl transfer reaction, needs to be released
from the complex to facilitate the binding to and the incorpo-
ration of the next nucleotide. Studies with other RNA and
DNA polymerases, including the reverse transcriptase (RT) of
human immunodeficiency virus type 1 (HIV-1), have shown
that the affinity to PPi is generally low, with the Kd (dissociation
constant) values being in the millimolar range (1, 13, 26). The
excision of the incorporated nucleotide analogues with HCV
NS5B requires concentrations of PPi in the high-micromolar
range, which is consistent with the notion that PPi is preferen-
tially released from the complex rather than being used as a
substrate. In contrast, the relatively low IC50s of compound A
point to the improved binding characteristics of compound A
compared with those of PPi. The specificity domain of the
inhibitor likely increases the affinity between the enzyme and
the inhibitor (29). At the same time, our data suggest that the
P156L and G152E mutations, which are associated with resis-
tance to pyrimidines, can diminish the binding of the inhibitor
through an altered interaction with the specificity domain. Nei-
ther P156L nor G152E affects pyrophosphorolysis; it is there-
fore unlikely that these mutations alter the interaction with the
anchor region of the inhibitor.
There are also several potential differences when the properties
of the dihydroxypyrimidine are compared with those of the PPi
analogue phosphonoformic acid (PFA or foscarnet), which shows
activity against various members of the Herpesviridae family and
HIV (22). PFA is a simple small molecule that does not contain
a specificity domain, yet this compound efficiently binds to viral
DNA polymerases. We have recently shown that PFA stabilizes
HIV-1 RT–nucleic acid complexes in the pretranslocational state
(3, 20). In this conformation, the nucleotide binding site is occu-
pied by the 3 terminus of the primer, which provides a mecha-
nism for the inhibition of DNA synthesis. The increase in the
stability of the complex is likely to be a result of a conformational
change that traps the inhibitor at the site that normally releases
the PPi product. As a consequence, PFA is able to inhibit RT
translocation, which, in turn, prevents the binding of the next
nucleotide. At this point it is unknown whether dihydroxypyrimi-
dines may bind to pre- and/or posttranslocational conformations
of NS5B-RNA complexes; techniques that allow a distinction
between the two complexes have yet to be developed. However,
the observation that increasing concentrations of the nucleotide
FIG. 5. Inhibition of excision and rescue by compound A. (A) In-
creasing concentrations of compound A up to 100 M were added
during a rescue reaction. The compound inhibited rescue by the wild-
type NS5B enzyme with an IC50 of 1.7  0.3 M, while the enzymes
with the G152E and P156L mutations required doses of compound A
that were at least an order of magnitude higher. (B) Compound A was
also added during an excision reaction to determine its effects directly
on pyrophosphorolysis. Data points are the means  standard devia-
tions for three independent experiments.
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substrate cause increases in IC50s likewise point to a competitive
mechanism of inhibition of RNA synthesis. Hence, the binding of
compound A to the pretranslocated complex and the inhibition of
HCV NS5B translocation or the binding of compound A to the
posttranslocated complex, which prevents nucleotide binding di-
rectly, are two possible scenarios that help to explain the inhibi-
tory effects of dihydroxypyrimidines.
Like the structurally related,-diketoacids, dihydroxypyrim-
idines can interfere with nucleotide incorporation and excision
during elongation. These findings are potentially relevant in
the development of new strategies to block HCV replication.
HCV NS5B is capable of excising 2-methylated nucleotide
analogues, which is detrimental to their inhibitory effects (6).
Although the significance of these findings has yet to be dem-
onstrated in biologically relevant settings, our data from cell-
free assays demonstrate that the incorporation of chain-termi-
nating nucleotides is reversible. Unlike current NNIs, which
appear to act exclusively at the level of initiation, potent PPi
mimics may counteract the excision reaction and may in turn
increase the potency of nucleoside analogue-containing drug
regimens. The differences in the mechanisms of action of PPi
mimics compared to those of established NIs and NNIs, along
with the different resistance profile, warrant further investiga-
FIG. 6. Competition of compound A with nucleotides or PPi. (A) The concentration of the PPi analogue required to inhibit 50% of an
elongation reaction was determined in the presence of different concentrations of UTP (100 nM, 1 M, 10 M). Lane C, a chain-terminated
product showing the results for position 16. (B) Similarly, IC50s were calculated during a rescue reaction with various concentrations of PPi (50
M, 100 M, 500 M). Lane C, CTP and UTP without PPi.
TABLE 1. IC50s of compound A required to inhibit nucleotide








UTP (0.1)..........................................................................257.7  174.6
UTP (1.0).......................................................................... 500
UTP (5.0).......................................................................... 1,000
PPi (50) .............................................................................173.6  16.6
PPi (100) ...........................................................................302.0  41.4
PPi (500) ...........................................................................881.9  93.5
a Data are means  standard deviations determined from three independent
experiments.
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tion into the development of dihydroxycarboxylate pyrimidines
as inhibitors of the HCV NS5B polymerase.
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